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Abstract
Methane-producing  archaea  have  recently  been  associated  with  disorders  of  the
gastrointestinal tract and dysbiosis of the resident microbiota. Some of these conditions
include inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)),
chronic  constipation,  small  intestinal  bacterial  overgrowth,  gastrointestinal  cancer,
anorexia, and obesity. The causal relationship and the putative mechanism by which
archaea may be associated with human disease are poorly understood,  as  are the
strategies to alter methanogen populations in humans. It is estimated that 30–62% of
humans produce methane detectable in exhaled breath and in the gastrointestinal tract.
However, it is not yet known what portion of the human population have detectable
methanogenic archaea. Hydrogen and methane are often measured in the breath as
clinical indicators of intolerance to lactose and other carbohydrates. Breath gas analysis
is  also  employed to  diagnose  suspected  small  intestinal  bacterial  overgrowth and
irritable bowel syndrome, although standards are lacking. The diagnostic value for
breath gas measurement in human disease is evolving; therefore, standardized breath
gas  measurements  combined with  ever-improving  molecular  methodologies  could
provide novel strategies to prevent, diagnose, or manage numerous colonic disorders.
In cases where methanogens are potentially pathogenic, more data are required to
develop therapeutic antimicrobials or other mitigation strategies.
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1. Introduction
1.1. Methanogen diversity in the gastrointestinal tract
Archaea represent the third domain of life, in addition to Prokaryota, which they more or
less physically resemble, and Eukaryota, with which they have more genetic similarities.
Many archaea are classified as extremophiles, but those which live in the digestive tract of
animals are known as methanogens. Archaeal diversity in the gastrointestinal tract (GIT) is
far less than that of bacteria, and more specifically monogastrics have a much lower diversity
as compared to herbivorous ruminant animals. In both host types, species belonging to the
genus Methanobrevibacter have been cited as the dominant methanogens in the GIT. In fact,
Mbr. smithii is the dominant species found in the human GIT, followed by Methanosphaera
stadtmanae [1–5]. This lack of relative diversity is largely a function of diet, the presence or
absence of other microorganisms, or digestive tract physiology, but it may play a role in
human intestinal dysbiosis. A general increase in microbial diversity has been correlated with
a  healthy  gut  microbiome that  is  resistant  to  physical  or  biotic  disruptions,  as  there  is
redundancy in metabolic pathways and the increased competition precludes dominance by
one particular taxon. Higher methanogen diversity was correlated with lower breath methane
production in humans [1].
Methanogens use hydrogen, in the form of free protons, H2 gas, NADH and NADPH cofactors,
acetate, or formate, to reduce carbon dioxide and produce methane gas. Thus, methanogens
rely on the by-products of bacterial fermentation of carbohydrates (i.e., carbon, hydrogen,
acetate, formate, or methanol) as precursor materials required for methanogenesis and their
own energy production. Dietary carbohydrates which are not broken down or absorbed by
the host are available to bacteria for fermentation [6], and a large amount of unused carbohy-
drates may consequently increase bacterial fermentation and archaeal methanogenesis. A diet
high in fiber and structural carbohydrates, which are largely indigestible to animal and human
enzymes (i.e., cellulose, hemicellulose, and lignin), is associated with populations of Methano‐
brevibacter ruminantium [7], while a diet high in starch and other easily digestible carbohydrates
is associated with Mbr. smithii [8, 9]. Mbr. smithii has been shown to improve polysaccharide
digestion by GIT bacteria and fungi, and even influence the production of acetate or formate
for its own use [10, 11]. Msp. stadtmanae requires methanol, a compound that is the by-product
of pectin fermentation, for its methanogenesis pathway, which accounts for its presence in
omnivores [1, 2, 5, 12].
Methanogens also have a slower growth rate than bacteria, which is sensitive to concentrations
of hydrogen required as an electron donor during methanogenesis, as well as other nutrients.
Few methanogenic taxa are motile, and these are limited to the order Methanococcales, and
the genera Methanospirillum, Methanolobus, Methanogenium, and Methanomicrobium (order:
Methanomicrobiales) [13, 14]. This difficulty of remaining situated in the intestines is a limiting
factor in methanogen density. In humans, methanogens tend to be denser in the left colon,
where fecal matter becomes more solid and transit time slows down [15], but they have also
been found in the small intestine [16]. In addition, passing through the gastric stomach is
challenging, which may explain why oral and intestinal populations of archaea and bacteria
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do not share an overlapping diversity [17, 18]. To overcome challenges to intestinal retention,
some species of methanogens have adapted to the human colon and are able to thrive. Mbr.
smithii produces surface glycans and adhesion-like proteins which improves their interaction
with host epithelia and allows for persistence in the gut, as well as wider range of fermentation
by-products, which can be used for methanogenesis, allowing for the flexibility of the human
diet [3].
1.2. Intestinal methane and the effect on the host
Colonic gases are among the most tangible features of digestion, yet physicians are typically
unable to offer long-term relief from clinical complaints related to excessive gas and associated
discomfort. Studies characterizing colonic gases have linked changes in volume or composition
to individuals with gastrointestinal disorders (see below). These studies have suggested that
hydrogen gas, methane, hydrogen sulfide, and carbon dioxide are by-products related to the
interplay between hydrogen-producing fermentative bacteria and hydrogen consumers
(reductive acetogenic bacteria, sulfate-reducing bacteria, and methanogenic archaea). The
primary benefit of methanogenesis in the GIT is to decrease hydrogen (hydrogen gas, NADH,
NADPH) resulting from carbohydrate fermentation by bacteria, protozoa, and fungi [19].
Hydrogen gas in the intestines can shorten intestinal transit times of feces by 10–47% [20].
Moreover, hydrogen has been shown to have antioxidant properties as an oxygen scavenger
[21, 22]. It is possible that in the healthy colon, physiological hydrogen concentrations might
protect the mucosa from oxidative insults, whereas an impaired hydrogen economy might
facilitate inflammation or carcinogenesis.
However, excessive hydrogen in the GIT can be detrimental to commensal microorganisms.
The decrease in hydrogen through the generation of inert methane gas helps to prevent
hydrogen damage to host or symbiotic microbial cells [23]. In ruminant animals, which have
a four-chambered stomach, methanogens associated with ciliate protozoa act as a hydrogen
sink [24], especially in the first two stomach chambers, the rumen and reticulum. There are a
few commensal protozoan species that can be found in the human intestinal tract [25], but it
is not yet known if they symbiotically interact with methanogens. Generally, this interaction
only occurs with protozoa that have a hydrogenosome organelle, which metabolizes pyruvate
and uses hydrogen ions as electron acceptors. In humans, the only protozoa that have a
hydrogenosome are trichomonads, such as Trichomonas hominis and Trichomonas tenax, both of
which are nonpathogenic [25, 26].
Alternative hydrogen sinks in humans include sulfate-reducing bacteria (SRB), which produce
hydrogen sulfide gas that is absorbed and detoxified by the liver, or acetogenic bacteria, which
produce the short-chain fatty acid acetate that can be metabolized by the host or other
microorganisms. Some of these pathways are mutually exclusive in humans, and either SRB
or methanogens will be present in large numbers [27]. Although higher hydrogen sulfide and
SRB levels have been detected in patients with irritable bowel disease (IBD), and to a lesser
extent in colorectal cancer (CRC), this colonic gas might have beneficial effects as a gaso-
transmitter [28]. Acetogens, on the other hand, have up to a 100 times higher hydrogen
concentration threshold, and thus cannot out-compete methanogens for precursors [29, 30].
The Pathology of Methanogenic Archaea in Human Gastrointestinal Tract Disease
http://dx.doi.org/10.5772/64637
21
Consequently, acetogenesis is rare in the human GIT, and if present is usually restricted to the
right colon [31].
Unlike hydrogen, there are as yet no known biological sinks for methane in the intestines [32],
although methanotrophic bacteria exist in a variety of water and soil environments. Instead,
some methane is excreted from the colon, and most is absorbed into the blood stream and
expelled from the lungs via exhalation. This allows methane production to be indirectly and
noninvasively measured, since breath methane concentration is correlated with methanogen
cell density in the intestines [1]. An undetectable concentration of breath methane does not
equate to the absence of archaea, and therefore false-negative interpretations of breath gas
analysis may result when breath methane is at undetectably low levels [33, 34]. Reported
estimations suggest that between 30 and 62% of healthy humans produce detectable methane
[31, 35]. The presence of methane gas in the intestines may influence or reduce intestinal transit
time, and the correlation between breath methane production and transit time has been
observed even in healthy individuals [19]. This was further examined using animal models, in
which the overabundance of methane gas caused a reduction in transit time while increasing
intestinal contractions [20, 36], thus increasing pressure inside the intestine by an average of
137% [20]. Alteration of intestinal motility may benefit slow-growing methanogen popula-
tions, which are limited by their ability to attach to host mucosal epithelia and maintain
themselves in the intestines.
This increased gas production and resulting pressure cause bloating, discomfort, flatulence,
or belching. In addition to detrimental physical effects, it has been speculated that methane
potentially causes chemical and biological effects as a “gaso-transmitter” [37], in the same way
that hydrogen sulfide affects smooth muscle activity [37] or nitrous oxide (N2O) is used in
biological systems to control vascular tone [38]. Studies using isolated gastrointestinal tissue
suggest that this interaction is between methane and enteric nervous tissue, rather than the
central nervous system [20]. Clinically, hydrogen and methane measured in breath can indicate
lactose and glucose intolerance, small-intestine bacterial overgrowth (SIBO), irritable bowel
syndrome (IBS), or other gastrointestinal diseases [35, 36, 39–42]. Therefore, standardized
breath gas measurements combined with ever-improving molecular methodologies could
provide novel strategies to prevent, diagnose, or manage numerous colonic disorders as
defined by the Rome III diagnostic criteria [43].
2. The role of archaea in metabolic disorders
Obesity in adults is most commonly defined using body mass index (BMI) (kg body weight/
height in meters squared), and for Caucasian adults, is defined as a BMI of ≥30 kg/m2. For over
a decade, shifts in intestinal bacteria diversity have been associated with weight gain or obesity
in humans, generally following an increase in the proportion of Firmicutes [44], a decrease in
Bacteroidetes, which has shown some anti-obesity influences [44–46], and with a shift in more
minor phyla. Generally, this shift in intestinal bacteria leads to an increase in host energy
harvest by improving polysaccharide digestion and host epithelial absorption which, in turn,
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causes weight gain [47–49]. Alternatively, a change in host genetics or immune system function
can also cause a shift in bacterial diversity. The lack of host immune-modulating factors, such
as Toll-like receptor 5 (TLR5) and fasting-induced adipocyte factor (Fiaf), produced insulin
resistance, increased adiposity (especially visceral), and shifted GIT bacterial diversity and
functionality in mice [49, 50]. Additionally, endotoxinemia, or the presence of microbial
endotoxins (e.g., lipopolysaccharide-A (LPS)) in intestines or blood, has been shown to induce
obesity, glucose intolerance, weight gain, and adiposity in response to a high-fat diet [51–53].
It would seem that bacterial diversity and density may have a specific role in metabolic
dysbiosis, as treatment with oral antibiotics has been shown effective at improving fasting and
oral glucose tolerance test (OGTT) levels in obese or insulin-resistant mice [54], or mitigating
endotoxinemia and reducing cecal LPS concentrations in mice on a high-fat diet [51, 55]. Both
obesity and diabetes are also correlated with low-grade chronic intestinal inflammation, likely
caused by bacterial LPS. The presence of LPS, among other systemic immune responses, causes
host macrophages to express pro-inflammatory cytokines, and in adipose-associated macro-
phages this only increases local insulin resistance and lipid storage [51, 53].
More recent studies have focused on the shifts in archaea associated with high-fat/high-cal-
orie diets or weight gain, especially as Mbr. smithii has been shown to increase polysacchar-
ide digestion by bacteria and fungi [10, 11] and may play a specific role in increasing
energy harvest. Mbr. smithii has been shown to increase in density in rats when switching
to a high-fat diet, and was associated with higher weight gain when given as a supplement
regardless of the diet [16]. In humans, BMI was higher in breath methane-positive subjects
(45.2 ± 2.3 kg/m2) than in breath methane-negative subjects (38.5 ± 0.8 kg/m2, P = 0.001) [56].
In a separate study, methane- and hydrogen-positive subjects again had higher BMI than
other groups (M+/H+ 26.5 ± 7.1 kg/m2, P < 0.02), and also had significantly higher percent
body fat (M+/H+ 34.1 ± 10.9%, P < 0.001) [41]. Interestingly, Mbr. smithii density was found
to be highly elevated in anorexic patients (5.26 × 108 rRNA copies/g feces), even more so
than in obese patients (1.68 × 108 rRNA copies/g feces), as compared to healthy body-
weight subjects (9.78 × 107 rRNA copies/g feces) [57].
Obesity is strongly associated with an increased risk for diabetes mellitus, or type-2 diabetes,
which is an inducible metabolic disease characterized by a lack of pancreatic production of
insulin, or a resistance to insulin at the cellular level. Type-1 diabetes is an autoimmune disease
characterized by the destruction of pancreatic beta cells which normally produce insulin.
Diabetes can lead to a host of other health problems, most especially cardiovascular disease,
renal failure, increased glaucoma and potential blindness, and reduced circulation, which
increases the risk for ulcers and infection in the peripheral limbs. Few studies investigate the
potential link between methanogens and diabetes. Type-1 diabetic patients with no complica-
tions showed a significant increase in intestinal transit time, although it was not associated
with other gastric symptoms [58]. Type-1 diabetes with an autonomic diabetic neuropathy
complication affects heart rate, blood pressure, perspiration, or digestion. Some patients with
this neuropathy have also been positive for SIBO [59, 60], which was associated with an
increased daily insulin requirement [60], or detectable methane production, which was
associated with a worse glycemic index [59]. Breath methane producers, which had compara-
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ble BMI and baseline insulin resistance to non-methane producers, had higher serum glucose
levels and a longer return to normal resting glucose after OGTT [61]. The mechanistic rela-
tionship between methanogens, methane, and diabetes has yet to be explained.
3. The role of archaea in colon cancer
Colorectal cancer is the most commonly diagnosed malignancy in the Western World, being
the fourth most common cancer diagnosis in the United States but the second leading cause
of cancer-related deaths [62]. In nonsmokers, it is the leading cause of cancer-related death
in men and the second leading cause of cancer-related death in women (after breast cancer).
The 5-year survival rate varies by stage and type, ranging from 53 to 92% [62]. All colorectal
cancers originate from adenomas or flat dysplasia, and are often asymptomatic, though oc-
cult bleeding may result and ultimately may be associated with an unexplained iron defi-
ciency anemia. Large tumors in the distal or left colon may result in a compromised bowel
lumen and potentially lead to symptoms including constipation, diarrhea, or bowel obstruc-
tion. The histopathology of CRC is complicated and involves a number of differently de-
fined molecular pathways. There is evidence of microbial dysbiosis in CRC patients, as well
as higher levels of breath methane in patients with CRC and premalignant polyps, as pre-
sented below.
Viral causative agents have been identified in a variety of cancers, but it is only recently that
prokaryotic- or eukaryotic-causative or protective agents have been investigated. Cancer has
been associated with a reduced bacterial diversity in the digestive tract [63], as well as in the
mammary glands [64]. Specific agents have been identified, which cause localized cancers
through their molecular interactions with host cells [65], such as Helicobacter pylori in stomach
cancers or a link between the diplomonad protozoan Giardia in pancreatic and gallbladder
cancer, but no archaea have yet been cited as a possible agent [66]. A recent review by Gill and
Brinkman [67] discusses the role of bacterial phages (viruses that exclusively infect bacteria)
in bringing mobility and virulence factors to bacteria, while archaea are infected by archaeon-
specific phages which are unlikely to have independently evolved similar virulence factors to
bacterial phages. Additionally, while archaea and bacteria are both prokaryotic, though in
different phylogenetic domains, there is little evidence of horizontal gene transfer between
them [67].
There is some discussion about the change in the density of methanogens in individuals with
colorectal cancer [33, 68, 69]. Methanogen density was shown to be inversely related to the
fecal concentration of butyrate, a short-chain fatty acid produced by bacterial fermentation
[70]. Butyrate has been shown to provide energy for digestive tract epithelia cells, upregulate
host immune system and mucin production, alter toxic or mutagenic compounds, and reduce
the size and number of crypt foci, which are abnormal glands in intestinal epithelia that lead
to colorectal polyps [71–73]. An altered gut microbiome in colorectal patients could shift
bacterial fermentation away from butyrate production to something more favorable to
methanogenesis.
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Methane production was increased in patients with precancerous symptoms and colorectal
cancer [39, 74], and was directly proportional to constipation but inversely proportional to
diarrhea in chemotherapy patients [75]. In the same study, pH was also directly proportional
to constipation but inversely proportional to diarrhea in chemotherapy patients [75]. Methane
itself has not been shown to be carcinogenic. However, the oxidation of methane forms
formaldehyde, which is carcinogenic [76]. On the other hand, hydrogen sulfide gas produced
by SRB has shown to promote angiogenesis (which tumors rely on), and has been shown to be
genotoxic when DNA repair is inhibited [77]. Colon cancer biopsies have shown an increase
in the enzyme cystathionine-β-synthase (CBS), which allows host cancer cells to produce their
own hydrogen sulfide, and a silencing of this gene was able to reduce tumor cell growth,
proliferation, and migration [78].
4. The role of archaea in irritable bowel syndrome
The symptoms of IBS vary between patients, and may include diarrhea, constipation, excess
flatus secondary to hydrogen or methane production, bloating, abdominal pain, and visceral
hypersensitivity [79]. Hydrogen sulfide gas from SRB was shown to increase luminal hyper-
sensitivity [80]. In addition, IBS is associated with changes in the diversity and density of
intestinal bacteria [42, 81–83], as well as with an increase in hydrogen production [84]. In
some patients with IBS, the change in bacterial populations is amplified, leading to SIBO. SI-
BO is also seen in non-IBS patients, but it is much more prevalent in IBS patients, especially
those with constipation as opposed to diarrhea [85, 86]. A common technique for the man-
agement of symptoms includes switching patients to a diet low in fermentable oligosacchar-
ides, disaccharides, monosaccharides, and polyols (FODMAPs) [87]. Two-thirds of patients
report symptoms linked to diet [88], especially gas production and bloating following inges-
tion of lactose [89], other carbohydrates, or fats [40, 88].
While the specific cause of IBS still remains unclear, the altered bacterial diversity causes a
shift in carbohydrate fermentation and altered gas production. If this shift favors methano-
genesis, the result is a decrease in transit time and an increase in constipation. The presence of
methanogens in the digestive tract, and the production of methane, has been associated with
patients with IBS, and especially with chronic constipation and reduced passage rate in the
intestines (slow transit) [42, 85, 90]. Methanogen density was found to be lower in IBS patients
as compared to controls [69, 91], although density and methane production were increased in
IBS patients with constipation as compared to IBS patients without constipation [90]. Metha‐
nobrevibacter spp. are increased with diets high in easily digestible carbohydrates, but de-
creased in diets high in amino acids/proteins and fatty acids [8], specifically Mbr. smithii [9].
More specifically, Mbr. smithii was higher in IBS patients with constipation and higher methane
production [90], and they have previously been shown as the dominant species in healthy
individuals who have high methane production [1].
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5. The role of archaea in inflammatory bowel disease
Contrary to recent findings in patients with IBS, low methane production [35, 42] and lower
methanogen density [69] were seen in patients with IBD, which includes the specific entities
Crohn’s and ulcerative colitis. In contrast to IBS, IBD patients demonstrate chronic inflam-
matory changes in the colon (UC) or in the small bowel, or a combination of small bowel
and colon involvement (CD).
Recently, it was demonstrated that two archaeal species normally found in the digestive
system, Mbr. smithii and Msp. stadtmanae, can have differential immunogenic properties in the
lungs of mice when aerosolized and inhaled [92]. Furthermore, Msp. stadtmanae was found to
be a strong inducer of the inflammatory response [92], and it is likely that this may occur even
in the GIT where it is normally found. Blais Lecours et al. [93] investigated the immunogenic
potential of archaea in humans relating to patients with IBD. Mononuclear cells stimulated
with Msp. stadtmanae produced higher concentrations of tumor necrosis factor (TNF) (39.5 ng/
ml) compared to Mbr. smithii stimulation (9.1 ng/ml) [93]. Bacterial concentrations and
frequency of Mbr. smithii-containing stools were similar in both healthy controls and patients
with IBD; however, the number of stool samples positive for the inflammatory archaea Msp.
stadtmanae was higher in patients than in controls (47 vs 20%) [93]. Importantly, only IBD
patients developed a significant anti-Msp. stadtmanae immunoglobulin G (IgG) response [93],
indicating that the composition of the microbiome appears to be an important determinate of
the presence or absence of autoimmunity. Recent advances in mucosal immunology and
culture-independent sequencing of the microbiome support the hypothesis that alterations in
the microbiota can alter the host immune response as is observed in IBD [94]. A specific role
for archaeal species has yet to be clearly defined.
6. The role of archaea in other intestinal dysbiosis
There are many rare gastrointestinal diseases and general conditions of dysbiosis which are
not well understood, but which may have a link to methane production in the intestines.
Pneumatosis cystoides intestinalis (PCI) is a condition in which gas-filled cysts occur in the
smooth muscle wall of the intestines, where it cannot be relieved by flatulence. It is believed
to be caused by bacteria in the intestinal wall. Interestingly, patients with PCI have lower
prevalence of breath methane production than patients with IBS, CD, UC, and even healthy
control subjects [35].
Non-IBS constipated patients with slow transit were more likely to have detectable levels of
breath methane (75 vs 44%) than constipated patients with normal transit, and both were more
likely to have detectable breath methane than nonconstipated controls (28%) [95]. This trend
was also reported in other studies [56, 85].
Diverticulitis, a condition involving the herniation of the intestinal mucosal and submucosal
layers back through the intestinal smooth muscle and creates pockets that harbor infections,
has only been noted since the early 1800s [96]. Interestingly, it is most common in the left colon
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in subjects from Western countries and the right colon in subjects from Asian countries [96],
which is likely a function of the “Western diet.” Diverticulitis was associated with a high
prevalence of methanogens in stool and high methane output [33], as well as fiber intake, age-
associated changes in the colon wall, low colonic motility, and high intraluminal pressure;
however, methane output was not associated with right colon diverticulitis [97]. As methano-
gen density is higher in the left colon [15], an increase in methane production that reduced
transit time and increased intraluminal pressure would seem to be a contributing factor to the
development of left colon diverticulitis.
7. Mitigation strategies
IBS is the most common functional gastrointestinal disorder and affects up to 12–15% of
adults in the United States. Roughly 1.6 million Americans currently suffer with CD or UC,
collectively known as IBD. IBS adversely impacts quality of life and medical expenditures,
with significant costs arising from health-care visits and reduced workplace productivity,
while IBD is a chronic, relapsing, debilitating disease associated with both environmental
and genetic factors. IBD affects one in 200 Americans (80,000 children) at an estimated direct
cost of $1.84 billion dollars. Conventional therapy attempts to modulate the immune re-
sponse in the gut as it relates to IBD, yet many individuals continue to require surgery to
control their disease or address its complications. There is a longstanding belief that dysbio-
sis (altered microbial environment) in the GIT plays an important etiologic role in the patho-
genesis of IBS and IBD. There is significant scientific and public interest in compositional
understanding of the intestinal microbiome (the specific constellation of microorganisms
populating the gut) to better understand the role of the microbiome in health and disease.
The contribution of individual organisms, including archaea, in the pathogenesis of GI dis-
ease is complex because of the rudimentary understanding of the compositional compo-
nents of the microbiome.
The control of methanogen populations has long been a strategy in livestock to improve animal
dietary efficiency, as methane production is an energy sink, as well as to reduce greenhouse
gas emissions. In ruminant livestock, as discussed in a review by Hook et al. [24], this is largely
done by manipulating the diet to improve the digestibility of feed and increase passage rate
through the digestive tract to both deprive methanogens of potential precursors and to
manually flush them out of the system. A change in diet is a potential avenue for reducing
methanogen populations in humans, as methanogenesis is associated with sugar-/starch-based
diets in monogastrics [27]. Environmental effects may also play a role, as children living near
landfills, which had higher atmospheric methane than areas away from landfills, had a higher
breath methane output and higher Mbr. smithii cell density than control children, regardless
of their socioeconomic level [34]. Previous to that study, it was shown that the bacterial and
fungal counts dispersed from landfills into air were up to 20 times higher than microbial counts
from other areas [98].
Antibiotics have commonly been used to treat gastrointestinal disease or symptoms such as
fasting and OGTT (glucose) levels [54], endotoxinemia and cecal LPS concentrations [51, 55],
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or global IBS symptoms [99]. Archaea are largely resistant to antimicrobial agents, which target
bacteria, as they have different cell wall components and structure, and the few antimicrobials
which they are susceptible to have been summarized in a recent review [100]. Notably,
Methanobrevibacter species have only been shown to be susceptible to mevastatin and levastatin,
both hydroxymethylglutaryl (HMG)-SCoA reductase inhibitors [101].
Our increasing knowledge of the potential long-term effects on gut microbial diversity has led
to a trend of alternative treatments or mitigating methods over antibiotics. A recent review of
probiotics showed them to be effective in relieving digestive dysbiosis symptoms or treating
gastrointestinal conditions [79, 81, 102, 103]. The use of prebiotics directly infused into the
colon, such as short-chain fatty acids, however, did not increase colonic motility [104]. While
probiotics and other dietary additives have been used to reduce methanogenesis in ruminant
livestock [24], the effect of probiotics on methanogen populations in humans has not yet been
investigated. While current research suggests that methanogens and methane production may
exacerbate symptoms, causative relations have only been shown in bacteria, and thus it is
bacteria which should be the ultimate target for mitigation strategies in unhealthy populations.
Direct microbial remediation and mitigation have only been recently considered in human
medicine with the advent of fecal transfer treatments from healthy donors. While this has
mainly been aimed at remediating pathogenic bacterial populations, the implications for this
technology to reduce methanogenesis and improve gastrointestinal conditions are clear. It may
be possible to use fecal transfer treatments to increase the diversity of GIT archaea and thus
promote competition to reduce methane production, to colonize with less-efficient methano-
gens, or to potentially increase competition by increasing SRB populations, which may have
its own health implications for detoxifying hydrogen sulfate gas. Most interestingly, the
transfer of fecal microbiota or cultures of specific methanogens has shown to also induce
metabolic states in the recipients; fecal transfers, or colonization from parent to child, from
overweight or pregnant individuals has been shown to increase weight gain in recipients [10,
16, 48, 105, 106]. While the possibility of this transfer to improve weight gain in severely
malnourished individuals remains possible but not yet clinically applied, the more commer-
cially appealing treatment of obesity using fecal transfers from lean individuals has yet to be
explored.
8. Summary
Methane has been implicated in a number of gastrointestinal diseases, but methanogens
have not yet been identified as causative agents. More work is needed in order to under-
stand the interactions between archaea and host epithelia, as well as whether the root dys-
biosis is caused by bacteria, archaea, or host epithelia. In addition, more sensitive, quick, and
minimally invasive assessment techniques are needed to assess methane production, metha-
nogen diversity, and methanogen density. In cases where methanogens are potentially
pathogenic, more data are required to develop therapeutic antimicrobials or other mitiga-
tion strategies.
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